Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 24, 2025 13:00 ET | Source: DelveInsight Business Research LLP

Multiple Sclerosis Clinical Trial Pipeline Shows Potential with Active Contributions from 60+ Key Companies | DelveInsight

New York, USA, June 24, 2025 (GLOBE NEWSWIRE) -- Multiple Sclerosis Clinical Trial Pipeline Shows Potential with Active Contributions from 60+ Key Companies | DelveInsight Multiple Sclerosis, the...
June 23, 2025 16:07 ET | Source: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions

Phase 1 clinical study of TERN-601 demonstrated differentiated profile in 28-day study; topline data were presented in September 2024 Phase 2 FALCON clinical trial of TERN-601 completed enrollment;...
June 17, 2025 07:00 ET | Source: Dyne Therapeutics, Inc.

Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting

- Based on Type C meeting and new data, Dyne submitted revised ACHIEVE trial protocol to FDA elevating vHOT to primary endpoint for U.S. Accelerated Approval - - New positive clinical data from Phase...
June 12, 2025 08:00 ET | Source: Third Harmonic Bio

Third Harmonic Bio Announces Stockholder Approval of Plan of Liquidation and Dissolution, Updated THB335 Phase 1 Clinical Data, and Initiation of Sale of THB335

Stockholders overwhelmingly approved liquidation and dissolution of the Company at the June 5, 2025 Annual Meeting Initial distribution currently expected in the range between approximately $5.30...
June 10, 2025 08:00 ET | Source: Vivex Biologics, Inc.

Vivex® Biologics, Inc. Appoints Industry Veteran Jon E. Block, Ph.D., as Chief Clinical Officer

MIAMI, June 10, 2025 (GLOBE NEWSWIRE) -- Vivex Biologics, Inc., a leader in developing and delivering innovative allografts, today announced the appointment of Jon E. Block, Ph.D., an industry...
June 10, 2025 08:00 ET | Source: CervoMed Inc.

CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization

Strengthening CMC leadership to prepare for scaled up neflamapimod manufacturing On track to initiate Phase 3 trial of neflamapimod in DLB in mid-2026 following meeting with regulatory authorities ...
June 04, 2025 07:00 ET | Source: Sionna Therapeutics, Inc.

Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis

SION-719 and SION-451 were generally well tolerated and achieved desired pharmacokinetic targets that reinforce their potential as either an add-on to standard of care or in a Sionna dual combination ...
June 02, 2025 13:17 ET | Source: Snail, Inc.

Snail Games Celebrates ARK Franchise’s 10-Year Anniversary with New Content and Global Community Events

CULVER CITY, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital...
June 02, 2025 10:25 ET | Source: Exactitude Consultancy

Medical X-ray Film Processing Device Market to Reach $2.5 Billion by 2034, Driven by 8.9% CAGR | Exactitude Consultancy

Luton, Bedfordshire, United Kingdom, June 02, 2025 (GLOBE NEWSWIRE) -- The global Medical X-ray Film Processing Device Market was valued at $1.2 billion in 2024 and is projected to grow at a CAGR of...
May 28, 2025 07:00 ET | Source: Entrada Therapeutics, Inc.

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Entrada Therapeutics announces that it has received authorization in the European Union to initiate its ELEVATE-45-201 clinical study.